Background The landscape of glioma research has evolved in the past 20 years to include
numerous large, multi-institutional, database efforts compiling either clinical data on glioma …

Venetoclax, the first approved BH3 mimetic targeting BCL2, demonstrates high response rate
in chronic lymphocytic leukemia (CLL) but resistant cases are emerging. Aside from BCL2 …

In the eighth edition of the American Joint Committee on Cancer staging system for breast
cancer, the definitions for T (tumor), N (nodes), and M (metastases) remain substantially …

Background. The landscape of glioma research has evolved in the past 20 years to include
numerous large, multiinstitutional, database efforts compiling either clinical data on glioma …

T cells mediate antigen-specific immune responses to disease through the specificity and
diversity of their T-cell receptors (TCRs). Although determining the spatial distributions of T cell …

Meningioangiomatosis (MA) is a rare entity characterized by the perivascular spread of
meningothelial and fibroblastic cells along the Virchow-Robin spaces of small leptomeningeal …

Peptide-based cancer vaccines are widely investigated in the clinic but exhibit modest
immunogenicity. One approach that has been explored to enhance peptide vaccine potency is …

Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma trials. Here, we
found that ICBs induce cerebral edema in some patients and mice with glioblastoma. …

Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Despite
advances in therapeutic intervention, including maximal tumor resection, chemotherapy, and …

We focus on innovative solutions to healthcare needs from biomedical engineering, clinical
engineering, and medical communities that bridge the engineering and clinical worlds. …